BR112014023570A2 - Purificação de cistationina beta-sintase - Google Patents

Purificação de cistationina beta-sintase

Info

Publication number
BR112014023570A2
BR112014023570A2 BR112014023570A BR112014023570A BR112014023570A2 BR 112014023570 A2 BR112014023570 A2 BR 112014023570A2 BR 112014023570 A BR112014023570 A BR 112014023570A BR 112014023570 A BR112014023570 A BR 112014023570A BR 112014023570 A2 BR112014023570 A2 BR 112014023570A2
Authority
BR
Brazil
Prior art keywords
beta
purification
cistationine
syntase
synthase
Prior art date
Application number
BR112014023570A
Other languages
English (en)
Other versions
BR112014023570B1 (pt
Inventor
Naveh David
P Kraus Jan
G Carrillo Richard
Majtan Tomas
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of BR112014023570A2 publication Critical patent/BR112014023570A2/pt
Publication of BR112014023570B1 publication Critical patent/BR112014023570B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin, biotin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

purificação de cistationina beta-sintase. a presente invenção refere-se a métodos cromatográficos para a purificação de uma proteína cistationina (beta)-sintase (cbs), particularmente, variantes truncadas da mesma e composições e composições farmacêuticas preparadas a partir da mesma. método que compreende as etapas de fornecer uma solução que contém cbs compreendendo impurezas e executar a separação cromatográfica da mesma.
BR112014023570-8A 2012-03-26 2013-03-25 Método de purificação da protéina cistationina betasintase (cbs) BR112014023570B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615629P 2012-03-26 2012-03-26
US61/615,629 2012-03-26
US13/830,494 US9243239B2 (en) 2012-03-26 2013-03-14 Purification of cystathionine beta-synthase
US13/830,494 2013-03-14
PCT/US2013/033716 WO2013148580A1 (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Publications (2)

Publication Number Publication Date
BR112014023570A2 true BR112014023570A2 (pt) 2021-06-01
BR112014023570B1 BR112014023570B1 (pt) 2022-03-15

Family

ID=49212017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023570-8A BR112014023570B1 (pt) 2012-03-26 2013-03-25 Método de purificação da protéina cistationina betasintase (cbs)

Country Status (11)

Country Link
US (4) US9243239B2 (pt)
EP (3) EP2831229B8 (pt)
JP (3) JP6146934B2 (pt)
CN (1) CN104540940B (pt)
AU (1) AU2013240003B2 (pt)
BR (1) BR112014023570B1 (pt)
CA (1) CA2867719C (pt)
HK (1) HK1246350B (pt)
IL (2) IL234635B (pt)
IN (1) IN2014DN07920A (pt)
WO (1) WO2013148580A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) * 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
LT3373922T (lt) * 2015-11-09 2022-04-11 The Regents Of The University Of Colorado, A Body Corporate Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme
EP3612214A4 (en) 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate OPTIMIZATION OF ALTERNATIVE ENZYMOTHERAPY FOR THE TREATMENT OF HOMOCYSTINURIA
US20220315965A1 (en) * 2019-06-25 2022-10-06 Zymergen Inc. Engineered biosynthetic pathways for production of cystathionine by fermentation
BR112021026292A2 (pt) * 2019-06-26 2022-05-31 Univ Colorado Regents Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
AU2003251550A1 (en) 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (zh) * 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
EP2531597B1 (en) 2010-02-04 2021-01-06 AEMase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase

Also Published As

Publication number Publication date
EP3263701A1 (en) 2018-01-03
US9243239B2 (en) 2016-01-26
US10941392B2 (en) 2021-03-09
US20130251700A1 (en) 2013-09-26
HK1246350B (zh) 2020-05-15
JP6952361B2 (ja) 2021-10-20
JP2020000259A (ja) 2020-01-09
AU2013240003A1 (en) 2014-10-02
EP3263701B1 (en) 2019-06-19
JP2015512639A (ja) 2015-04-30
IL263162A (en) 2018-12-31
JP6146934B2 (ja) 2017-06-21
CA2867719A1 (en) 2013-10-03
EP2831229B1 (en) 2017-10-18
AU2013240003B2 (en) 2018-04-19
US10160962B2 (en) 2018-12-25
US20160177287A1 (en) 2016-06-23
EP3569706A1 (en) 2019-11-20
IL263162B (en) 2019-11-28
CA2867719C (en) 2020-08-11
IN2014DN07920A (pt) 2015-05-01
CN104540940A (zh) 2015-04-22
US20190055537A1 (en) 2019-02-21
IL234635B (en) 2018-12-31
CN104540940B (zh) 2018-03-06
JP2017121255A (ja) 2017-07-13
JP6839595B2 (ja) 2021-03-10
WO2013148580A1 (en) 2013-10-03
EP2831229B8 (en) 2018-10-17
EP2831229A1 (en) 2015-02-04
US20200131497A1 (en) 2020-04-30
BR112014023570B1 (pt) 2022-03-15

Similar Documents

Publication Publication Date Title
BR112014023570A2 (pt) Purificação de cistationina beta-sintase
MY166016A (en) Infant nutrition for improving fatty acid composition of brain membranes
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112013003332A2 (pt) método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado
IN2014DN08481A (pt)
IL248549A0 (en) A process for purifying vitamin K depends on proteins such as coagulation factor ix
BR112012025729A2 (pt) purificação por adsorção de caramelo
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
WO2014068586A3 (en) Solid oral compositions of tolvaptan
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
ZA201407010B (en) Process for the preparation of branched polybutadiene having high content of 1,4-cis units
BR112015022859A2 (pt) processo para fabricação de mono-hidrato trissódico gadofosveset
BR112013020212A2 (pt) método de produção de um adoçante natuarl aprimorado
EP2844631A4 (en) PROCESS FOR PURIFYING RAW ACETONE CURRENT
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
WO2012122451A3 (en) Polymorphs of maxacalcitol and process for the preparation of maxacalcitol
EP2924044A4 (en) PLATINUM COMPOUND AND MALONIC ACID DERIVATIVE HAVING A CONTAINING GROUP CONTAINING AN AMINO OR ALKYLAMINO GROUP
BR112015001564A2 (pt) métodos para a remoção de um ou mais componentes de uma composição ou composições.
IN2015DN00725A (pt)
MY187748A (en) Compositions and method for maintaining/improving cognitive function
BR112015014539A2 (pt) método para purificação de lecitina
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
IL237978A0 (en) A high safety process for the preparation of purified fractions of stem cells
IN2013MU03317A (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2013, OBSERVADAS AS CONDICOES LEGAIS.